Latest News and Press Releases

In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of...

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus...

33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent,...

Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to...

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results...

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD,...

Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs um +15% (kWk1, +12% USD), das operative Kernergebnis1 verbesserte sich um +27% (kWk, +23% USD)Das Umsatzwachstum beruhte auf...

Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto...

 Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation...

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of...